Literature DB >> 31451572

Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays.

Patrick Murray1, Charles Cooper2, Courtney Maus3.   

Abstract

Keywords:  BD MAX MDR TB; INH resistance

Year:  2019        PMID： 31451572      PMCID： PMC6711926          DOI： 10.1128/JCM.00779-19

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  5 in total

1.  GeneXpert MTB/RIF Is Superior to BBD Max MDR-TB for Diagnosis of Tuberculosis (TB) in a Country with Low Incidence of Multidrug-Resistant TB (MDR-TB).

Authors:  E M Mokaddas; S Ahmad; H S Eldeen
Journal:  J Clin Microbiol       Date:  2019-05-24       Impact factor: 5.948

2.  Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996-2005.

Authors:  E Mokaddas; S Ahmad; I Samir
Journal:  Int J Tuberc Lung Dis       Date:  2008-03       Impact factor: 2.373

Review 3.  Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis.

Authors:  Medea Gegia; Nicholas Winters; Andrea Benedetti; Dick van Soolingen; Dick Menzies
Journal:  Lancet Infect Dis       Date:  2016-11-17       Impact factor: 25.071

4.  The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis: A modelling study.

Authors:  Kamila Romanowski; Jonathon R Campbell; Olivia Oxlade; Federica Fregonese; Dick Menzies; James C Johnston
Journal:  PLoS One       Date:  2019-01-24       Impact factor: 3.240

5.  Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.

Authors:  Noura M Al-Mutairi; Suhail Ahmad; Eiman Mokaddas; Hanaa S Eldeen; Susan Joseph
Journal:  BMC Infect Dis       Date:  2019-01-03       Impact factor: 3.090
  5 in total
  3 in total

1.  Reply to Murray et al., "Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays".

Authors:  Eiman M Mokaddas; Suhail Ahmad; Hanaa S Eldeen
Journal:  J Clin Microbiol       Date:  2019-08-26       Impact factor: 5.948

Review 2.  Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.

Authors:  Samantha Pillay; Karen R Steingart; Geraint R Davies; Marty Chaplin; Margaretha De Vos; Samuel G Schumacher; Rob Warren; Grant Theron
Journal:  Cochrane Database Syst Rev       Date:  2022-05-18

3.  The Performance of the Abbott Real Time MTB RIF/INH Compared to the MTBDRplus V2 for the Identification of MDR-TB Among Isolates.

Authors:  Anura David; Lyndel Singh; Pedro Da Silva; Lesley Scott; Wendy Stevens
Journal:  Infect Drug Resist       Date:  2020-09-28       Impact factor: 4.003
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.